Pillar guide
UK Longevity Clinics: The 2026 Editorial Guide for Adults Considering Preventative Health
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Published Tue May 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Hero capsule
The UK longevity clinic market in 2026 looks roughly the way private GP medicine looked in 2008: six or seven mainstream operators, a clear cost ladder running from about £2,000 to north of £15,000, and a fairly tight protocol that most of them now share. A “longevity clinic” in this country generally means a structured baseline of blood biomarkers, advanced imaging, body composition, an optional continuous glucose monitor trial, a hormone audit, and a planned follow-up loop over twelve months. The six clinics covered here are the ones a UK adult would most plausibly walk into this year: Hooke, Echelon Health, Reliant Healthcare, Human Longevity’s UK arm, Bupa Health Clinics’ longevity offering, and Nuffield Health. The aim of this piece is editorial, not promotional. PeptideClear does not recommend a clinic for a specific person.
What a longevity clinic actually does in 2026
Strip the marketing back and the year-one protocol across the mainstream UK clinics is more standardised than the brochures suggest. The shape almost always looks like this.
A baseline blood panel that goes well past the NHS standard set. Most clinics now run somewhere between 60 and 100 markers on the first visit: full lipid panel including ApoB and Lp(a), HbA1c, fasting insulin, full thyroid including free T3 and reverse T3, sex hormones, cortisol, vitamin D, B12, ferritin, full liver and kidney function, full blood count, hsCRP, homocysteine, urate, and increasingly a metabolic add-on (omega-3 index, GlycA, sometimes urinary metabolomics).
Advanced imaging in some combination. The most common pairing in 2026 is a whole-body MRI screen (covering brain, thorax, abdomen and pelvis, sometimes prostate or pelvis-specific protocols for women), a cardiac assessment (CT coronary calcium score at the budget end, cardiac MRI or stress echo at the premium end), and a DXA scan for bone density and body composition. A handful of clinics now add CT lung screen for current or former smokers and ultrasound carotid intima-media thickness for cardiovascular layering.
Body composition and functional testing. DXA is the headline reading. VO2max via CPET (cardiopulmonary exercise testing) appears in roughly half the packages. Grip strength, gait speed, and a short cognitive battery are common.
A continuous glucose monitor trial. Almost universal at the mid and upper tiers. Usually two weeks, occasionally four. The output is a personalised glycaemic profile rather than a diabetes screen, which the HbA1c already covers.
A hormone audit. Tighter than the NHS standard. For men, total and free testosterone, SHBG, oestradiol, DHEA-S, sometimes IGF-1. For women, the same panel adapted, plus FSH/LH and AMH where relevant for perimenopausal staging.
Cardiovascular layering. ApoB is now the lead marker at most clinics. Lp(a) is measured once as a lifetime reading. The CT coronary calcium score has displaced the older cholesterol-only framing in everything except the lowest-cost packages.
Follow-up consultations. Typically two to four over the year, with one comprehensive review at month six or twelve. Some clinics now add a quarterly biomarker re-test on a subset of markers, others save the full re-test for year two.
That is the shape. What varies between clinics is depth, the calibre of the consultant on the other side of the table, the prestige and quality of the imaging suite, the structure of the follow-up loop, and whether the clinic prescribes medications themselves or refers you back to your GP. Cost variance, which we come to next, mostly tracks imaging depth, consultant time, and follow-up frequency rather than the underlying blood panels, which converge.
The six UK clinics compared
Hooke
Hooke is the most consumer-forward of the new wave. Positioned as a “longevity membership” rather than a single annual MOT, with London premises and a tech-product feel to the app and member dashboard. Founded in the last few years, it has grown quickly on word of mouth in the founder and creative-industries crowd.
The baseline package sits at around £2,800 to £3,500 for the first year depending on add-ons, with a continuing annual membership at a lower rate. Included in year one: full extended blood panel, DXA, MRI screen (varies by tier), CGM trial, hormone audit, and a structured consultant consultation pathway. The follow-up loop is the part Hooke is strongest on: members can message a clinician inside the app, results are pushed in plain English, and the year is built around four touchpoints rather than a one-off report.
Strengths. Reasonable price for what is included. Clean digital experience, which matters more than people expect once you are interpreting your own results six months later. London logistics are easy.
Weaknesses. Imaging is more limited than at Echelon or Human Longevity. The MRI protocol is screening-grade rather than the multi-region, multi-sequence depth at the premium end. If you specifically want cardiac MRI or a near-comprehensive cancer screen, Hooke is the wrong front door. Also: at the time of writing, premises are London-only, so anyone outside the M25 is travelling.
Where the value sits. Hooke is the best value at the mid tier for a UK adult who wants the structure of a longevity protocol without paying premium imaging prices, and who values an actual ongoing relationship over a one-shot annual report.
Echelon Health
Echelon Health is the original UK premium player and remains the imaging benchmark. London-based, founded over a decade ago, and built around the principle that early detection through deep imaging is the highest-value preventative intervention available privately.
The flagship package, the “Platinum” assessment, runs at around £11,000 to £13,000. There is a more selective “Gold” package in the £5,000 to £7,000 band. The Platinum tier includes CT coronary angiogram (not just calcium score), full-body MRI, CT chest, DXA, full extended blood work, plus a depth of consultant time that is hard to find at lower price points.
Strengths. Imaging depth is the clear differentiator. Echelon publishes detailed protocols and has been doing this longer than anyone else in the UK. If your concern is “I want to find anything serious as early as possible”, this is the package mainstream UK clinicians most often respect.
Weaknesses. Cost. The follow-up loop is leaner than at Hooke or Bupa; Echelon’s model is closer to “comprehensive annual” than “twelve-month relationship”. And there is less emphasis on lifestyle, hormonal optimisation, or behavioural change inside the package itself: you are paying for diagnostic depth, not coaching.
Where the value sits. Echelon makes sense for a UK adult over 45 with a family history of cardiovascular disease or cancer, financial headroom, and a preference for diagnostic depth over ongoing coaching.
Reliant Healthcare
Reliant Healthcare occupies an interesting middle position. Less consumer-branded than Hooke, less premium-imaging than Echelon, more clinical-feeling than either. Operates out of central London with a referral network across the UK for imaging.
Packages typically run £4,000 to £8,000 depending on imaging scope. Standard inclusions are extended blood work, DXA, hormone audit, CGM, MRI screen, and a consultant-led review session. Reliant’s pitch has historically been “private consultant medicine that takes longevity seriously” rather than “longevity clinic that happens to be medical”.
Strengths. The consultant relationship is the strongest part. Several Reliant clinicians are dual-credentialled in their NHS specialties, which gives the follow-up consultation a different feel from a clinic where the lead practitioner is brand-new to the longevity space. Useful if your panel of concern is specific (cardiac, endocrine, etc.) and you want a consultant with deep specialty roots.
Weaknesses. Less polished consumer experience than Hooke. The annual structure is more flexible (good for some, ambiguous for others). Imaging is solid but not at Echelon depth.
Where the value sits. Reliant suits an adult who values the seniority and specialty depth of the consultant over the digital wrapper, and who wants real flexibility to adjust the protocol around an actual clinical concern rather than a generic longevity menu.
Human Longevity (UK arm)
Human Longevity is the UK arm of the US franchise originally co-founded by Craig Venter. The brand carries weight in genomics and the protocol reflects that: the package includes whole-genome sequencing in addition to the standard imaging and biomarker work. UK operations have been more selective and lower-profile than the US flagship in San Diego, but the protocol is recognisable.
Cost sits at the top of the market, broadly £12,000 to £15,000+ depending on configuration. Beyond the standard imaging and blood panel, the headline differentiators are whole-genome sequencing, deeper microbiome and metabolomics panels at some tiers, and a more research-flavoured analytical write-up.
Strengths. Genomics is the genuine differentiator. If the prospect of having your full genome sequenced, interpreted, and integrated into the clinical narrative is the part you actually want, Human Longevity is the cleanest UK route to it inside an integrated longevity package. The analytical depth on the report is also unusually high.
Weaknesses. The “what do I do with this” gap is real. Whole-genome data is a long-tail asset whose practical clinical actionability in 2026 is still narrow outside specific oncogenetic, cardiomyopathic, or pharmacogenomic findings. Most adults will find the actionable part of the report overlaps heavily with what Echelon or Hooke produced at a lower price.
Where the value sits. Human Longevity is the right call for someone who specifically wants whole-genome sequencing inside an integrated package and has the budget, or who has a specific genetically-loaded family history (early cardiac death, BRCA-line cancer profile) where the genomics layer is doing real diagnostic work rather than ornamental work.
Bupa Health Clinics longevity offering
Bupa is the most accessible name on this list and arguably the most underrated. The Bupa Health Clinics longevity package has matured significantly in the past two years and now offers a structured baseline assessment that compares respectably to the new boutique brands, with the operational scale Bupa already had in place.
Cost runs roughly £2,000 to £4,500 depending on add-ons and member status. Inclusions: extended blood panel, MRI screen (regional or whole-body depending on tier), DXA, cardiovascular assessment, hormone audit, CGM trial at the upper tier, and a consultant review. Bupa members can sometimes access a reduced rate.
Strengths. Coverage. Bupa has clinics across the UK, which is a meaningful advantage for anyone outside London. The price is competitive at the entry tier. The clinical governance is what you would expect from a long-established UK private provider, with no early-stage-startup risk.
Weaknesses. The longevity branding inside Bupa is layered onto an existing health-assessment framework, which means the package can feel less integrated than at the boutiques. Follow-up loops are typically less intensive than at Hooke or Reliant. Some advanced markers (Lp(a), GlycA, advanced metabolomics) are not standard at the lower tiers and need to be specifically requested.
Where the value sits. Bupa is the strongest mainstream entry point for an adult outside London who wants a credible longevity baseline at a sensible price, without committing to a £10,000+ assessment.
Nuffield Health
Nuffield Health is the other mainstream UK private provider running structured health assessments at scale. Nuffield’s “360 Health Assessment” series predates the current longevity branding by a decade, and the upper tier of that series, now usually marketed under a longevity framing, lands in the same conceptual space as the Bupa offering.
Cost runs roughly £900 to £4,000 depending on the assessment chosen, with the longevity-aligned tier sitting at the upper end. Inclusions at the top tier: extended blood panel, body composition, cardiovascular assessment including ECG and sometimes calcium score, lifestyle and fitness assessment (Nuffield’s fitness pedigree shows here), and a consultant review.
Strengths. Like Bupa, geographic coverage across the UK is the structural advantage. Nuffield’s fitness and rehab integration is genuinely different from any other clinic on this list: VO2max, functional testing, and gym-integrated follow-up are areas where Nuffield has a real institutional edge. Price is keen.
Weaknesses. Imaging is the weak link. Whole-body MRI is not standard at most Nuffield tiers and would need to be added or arranged separately. The longevity branding is newer to Nuffield than the assessment business itself, so some of the cutting-edge biomarker work (ApoB as headline, Lp(a) baseline, GlycA, advanced metabolomics) varies clinic-by-clinic rather than being a uniform national offering.
Where the value sits. Nuffield is the strongest fit for an adult whose longevity priority is functional capacity, fitness, and structured follow-up coaching, rather than maximum diagnostic imaging depth. The combination of a credible baseline plus integrated fitness follow-up at sub-£3,000 is unmatched on this list.
What you actually get from £2k vs £15k
The honest answer is: the £2k package and the £15k package will agree about ninety percent of the time on the core preventative health story. Where the £15k package earns its premium is in the long tail of detection.
A £2k baseline (Hooke entry, Bupa standard, Nuffield upper tier) gives you a thorough biomarker map, a reasonable cardiovascular reading, body composition, and a hormone snapshot. It will detect most type 2 diabetes prodromes, most thyroid issues, most overt lipid disorders, most testosterone deficiencies, and most early signs of advanced biological ageing. It will not reliably detect early-stage occult cancer, asymptomatic coronary plaque burden in a person with normal lipids, or subtle cardiomyopathic changes.
A £15k assessment (Echelon Platinum, Human Longevity at the top configuration) is structurally aimed at the long tail. Whole-body MRI, CT coronary angiography, deep genomics, and the consultant time to interpret what comes back. Statistically, most adults walking into such a package will leave with reassurance and a manageable set of lifestyle priorities, not a diagnosis. The premium pays for the small probability of catching the thing that the £2k package would have missed.
A useful framing: if your worry is “I want to know if my metabolism, hormones and cardiovascular markers are roughly where they should be, and I want a structured year”, the £2k package is enough. If your worry is “I want maximum confidence that I am not currently carrying an undetected cancer or significant cardiovascular plaque”, the £15k package is doing different work and you are paying for the imaging.
Neither answer makes the other one wrong. Two adults with different family histories, financial profiles and risk tolerances can both choose rationally.
The peptide intersection
A live editorial question for PeptideClear readers: where do peptides sit in the UK longevity clinic landscape in 2026? The answer is more boring and more honest than the social-media discourse suggests.
A small number of UK longevity clinics prescribe peptide medications under their actual licensed indication. The clearest current example is tesamorelin, a growth hormone releasing hormone analogue licensed in some markets for HIV-associated lipodystrophy. A handful of UK private consultants will prescribe tesamorelin to patients who meet the licensed indication, through standard private prescription routes. That is genuine prescription-tier peptide medicine. The clinics will not generally prescribe it off-label as a “longevity” intervention to an asymptomatic adult.
The much larger category, the so-called “research peptides” (BPC-157, MOTS-c, ipamorelin, CJC-1295, and so on), is a separate market and a separate regulatory class. None of the six longevity clinics covered above prescribes those substances. They are sold in the UK only as research chemicals, not for human use. PeptideClear covers them on the research-peptide pages explicitly under that framing.
The clinical reality, which is worth saying clearly: most of the peptide questions a longevity-curious adult will arrive with sit outside what a UK longevity clinic will engage with. A licensed prescriber within the GMC system is unlikely to take on prescription responsibility for an unlicensed substance with thin human RCT evidence. That is not the clinic being conservative for branding reasons. It is how UK prescription medicine works.
If you want a clinic relationship that takes peptide questions seriously inside the licensed framework, the longevity clinics on this list will engage on tesamorelin, semaglutide and tirzepatide (the GLP-1 class), and a small number of other licensed peptide medications. If you want a clinic that will prescribe BPC-157 or MOTS-c to an asymptomatic adult, you will not find one inside the UK regulated system, and PeptideClear does not recommend you go looking outside it.
Outcome metrics that matter
A longevity clinic that does not give you a small number of meaningful trackable outcomes is selling you a one-shot report rather than a relationship. The four metrics that show up across the credible packages, and that are worth tracking year over year, are these.
Biological age. Several methylation-based estimators are now in clinical use, and the methodology has matured significantly since the early consumer panels. Year-on-year movement in a single estimator (rather than the absolute number) is the useful signal.
ApoB. The single most informative cardiovascular biomarker for the general adult population in 2026. Has structurally displaced LDL-cholesterol as the lead lipid marker in the cardiology literature. Year-on-year trend is what matters; the snapshot is less informative.
VO2max. Cardiopulmonary exercise testing remains one of the most all-cause-mortality-predictive measurements available in clinical practice. The literature on VO2max as a longevity marker is unusually robust. Some clinics measure it directly via CPET; others estimate it from sub-maximal protocols, which is less accurate but still tractable.
Lean mass percentage and bone density (DXA). The two body composition readings that matter long-term, particularly for adults over 40. Lean mass trajectory through midlife and bone density at peri- and post-menopausal transition are signals you want to be tracking explicitly.
There are other useful markers (Lp(a) as a one-shot lifetime reading, GlycA as an inflammation composite, fasting insulin as a metabolic early warning). The four above are the ones that show up as meaningful trends across consistent year-on-year measurement, which is what makes them worth the recurring cost of a longevity clinic relationship rather than a single assessment.
What we are NOT saying
PeptideClear is an editorial and comparison service, not a clinic. This piece is informational and does not constitute clinical advice.
These clinics are not NHS-equivalent. The NHS provides primary care, urgent care, hospital medicine, and a structured set of screening programmes (cervical screening, breast screening, bowel screening, the AAA programme, and so on). Private longevity clinics provide a different service: predominantly asymptomatic-screening medicine outside the NHS pathway. The two are not substitutes. Anyone with a current clinical concern should see their GP first.
Clinical decisions remain between you and your prescriber. Nothing in this guide tells you whether to have a CT coronary angiogram, whether to start a statin, whether to ask for a tesamorelin prescription, or whether to act on any individual finding. Those decisions involve your full clinical picture and they belong to you and a licensed UK clinician.
PeptideClear does not recommend a clinic for a specific person. The six clinics in this guide are described editorially. We do not know your risk profile, family history, budget, postcode, or what you specifically want out of a longevity engagement. If a clinic on this list looks like a fit, do your own due diligence: read their published protocols, speak to their intake team, and ask the questions that matter to you before booking.
FAQ
Is longevity clinic medicine evidence-based?
In parts. The underlying biomarkers (ApoB, Lp(a), HbA1c, hsCRP, DXA-derived body composition, VO2max) sit on robust clinical literature. The screening MRI and CT components have evidence bases that are stronger for some indications (CT coronary calcium scoring in intermediate-risk adults) than others (whole-body MRI in low-risk asymptomatic adults remains debated in the radiology literature). The lifestyle interventions that follow are evidence-based to varying degrees, and the genomics layer is highly variable. “Evidence-based” is not a binary; the honest answer is that the protocols are partly evidence-based, partly defensible inference, and partly emerging practice.
What does the NHS cover versus a private longevity clinic?
The NHS covers reactive medicine and a small number of structured screening programmes. It does not provide asymptomatic comprehensive screening of the kind a longevity clinic offers (no NHS whole-body MRI for asymptomatic adults, no NHS calcium score in most regions, no NHS DXA outside specific osteoporosis pathways). The trade-off is that private screening generates a higher rate of incidental findings that then need follow-up, sometimes back through the NHS.
Can I just get the same tests cheaper elsewhere?
For the biomarkers, often yes. Several UK private blood testing services (Medichecks, Thriva, Randox Health) offer extended blood panels at prices well below what a longevity clinic charges for the same markers. What you lose is the integrated consultant interpretation and the imaging layer. If you are confident interpreting your own blood work and you do not currently want imaging, the bloods-only route is rational. If you want the integrated package and a clinical relationship, you are paying for that integration.
Is whole-body MRI a good idea for asymptomatic adults?
This is genuinely contested in the radiology literature. The case for: occult tumours and structural abnormalities can be detected early. The case against: high incidental-finding rate, with downstream investigation cost (and anxiety) for findings that would never have caused harm. Different radiologists give honest readers different answers. It is a personal decision and worth discussing with your GP before committing.
Will a longevity clinic prescribe me peptides?
A UK longevity clinic will prescribe licensed peptide medications (the GLP-1 class, tesamorelin under its licensed indication) where clinically appropriate for the patient in front of them. It will not prescribe the so-called research peptides (BPC-157, MOTS-c, and so on) because those substances are not licensed for human use in the UK. See the peptide intersection section above.
How do I choose between the six clinics on this list?
Start with your honest priority. If it is imaging depth, Echelon Health is the clearest call. If it is genomics, Human Longevity. If it is an ongoing digital-first relationship at a mid-tier price, Hooke. If it is consultant seniority and clinical specialty depth, Reliant Healthcare. If it is geographic coverage at a sensible price, Bupa Health Clinics. If it is functional capacity and integrated fitness follow-up, Nuffield Health. Then check premises, consultant availability, and total year-one cost against your budget.
Sources
Sniderman AD et al. ApoB versus LDL-C in primary prevention. JAMA Cardiology. PMID: 30810265.
Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and risk of myocardial infarction. European Heart Journal, 2020. PMID: 31504442.
Tsimikas S. A test in context: lipoprotein(a). Journal of the American College of Cardiology, 2017. PMID: 28132721.
Ross R et al. Importance of assessing cardiorespiratory fitness in clinical practice. American Heart Association Scientific Statement. Circulation, 2016. PMID: 27881567.
Mandsager K et al. Association of cardiorespiratory fitness with long-term mortality. JAMA Network Open, 2018. PMID: 30646252.
Shepherd JA et al. Body composition by DXA. Bone, 2017. PMID: 28042037.
Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019. PMID: 30312372.
Greenland P et al. Coronary calcium score and cardiovascular risk. Journal of the American College of Cardiology, 2018. PMID: 29622161.
Falk RH, Gerstenblith G. Whole-body MRI for asymptomatic screening: the debate. Radiology, ongoing literature. (Editorial commentary, no single PMID.)
Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 2018. PMID: 29643443.
Falutz J et al. Tesamorelin in HIV-associated lipodystrophy. New England Journal of Medicine, 2007. PMID: 18046027.
Echelon Health published Platinum and Gold protocols, 2026.
Hooke published membership tier breakdown, 2026.
Bupa Health Clinics published health assessment specifications, 2026.
Nuffield Health 360 Health Assessment specifications, 2026.
Human Longevity Inc. published Health Nucleus protocol, 2026.
Reliant Healthcare published assessment specifications, 2026.
NHS screening programme summary, gov.uk, 2026.
UK Royal College of Radiologists position on incidental findings in screening imaging, 2024.
Author: Oliver Mackman. Published 19 May 2026. Editorial only. PeptideClear is a comparison and information service, not a clinic. Clinical decisions remain between you and your UK prescriber. See /editorial-policy and /how-we-are-funded.